TWM
CRSP icon

Triton Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Triton Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,102
Closed -$396K – 97
2021
Q3 		$396K Sell
4,102
-45
-1% -$5.65K 0.19% 64
2021
Q2 		$547K Sell
4,147
-53
-1% -$6.45K 0.31% 55
2021
Q1 		$502K Buy
4,200
+73
+2% +$11K 0.34% 59
2020
Q4 		$663K Buy
+4,127
New +$488K 0.42% 29

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Triton Wealth Management's CRSP Position: Q4 2021 in Review

Triton Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 4,102 shares — an estimated $396K sold.

Triton Wealth Management first reported a position in CRSP in Q4 2020 and held it in 4 quarters. The position peaked at $663K in Q4 2020. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Triton Wealth Management reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Triton Wealth Management sold 4,102 CRISPR Therapeutics shares in Q4 2021, an estimated $396K.
  • Triton Wealth Management first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 4 quarters.
  • Triton Wealth Management's CRISPR Therapeutics position peaked at $663K in Q4 2020.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Triton Wealth Management's 13F filing for Q4 2021, filed 7 Feb 2022.